DAS181 treatment for COVID-19 lung infection in immune-compromised adults
Part of Infections, Lungs & breathing clinical trials.
This Phase 3 trial tests DAS181 to treat lower lung (chest) viral infections in people with weakened immune systems, including a COVID-19 subgroup. It may help by targeting certain viruses in the lungs, but joining depends on your oxygen needs, recent diagnosis, and other safety factors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You need extra oxygen right now (at least 2 liters per minute) because your blood oxygen is low
- You are immunocompromised, such as from a prior transplant, certain cancers needing chemotherapy, or another immune system problem
- You had a confirmed lower lung viral infection within the last 3 days
- For the COVID-19 group: you’re age 18 or older and have a COVID-19 lung infection seen on CT in at least two lung sections
- For the COVID-19 group: COVID-19 must be confirmed in a lung or respiratory sample (by lab test)
- You can follow study steps and you give signed informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibody medicine for people with COVID-19 who are at high risk of getting very sick. If you qualify, you would receive the study drug or a placebo (inactive substance) to see if it helps you recover without needing to go to the hospital.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
This trial tests an experimental drug called S-337395 for adults with RSV who are not in the hospital but are at high risk for severe illness. It aims to see if the drug can help prevent symptoms from getting worse.
This trial tests if remdesivir can safely treat RSV (a respiratory virus) in people with weakened immune systems, such as those who have had a stem cell or bone marrow transplant, CAR T-cell therapy, or are being treated for blood cancer. If you have a confirmed RSV infection in your nose or throat and are at moderate or high risk for complications, you may be able to join.
This trial tests an inhaled medicine (PUL-042) for people with blood cancers or who have had a stem cell transplant and now have a respiratory virus (parainfluenza, RSV, or human metapneumovirus). The goal is to see if the drug can help clear the virus and improve symptoms.
This trial tests whether an experimental drug called AP1189, added to standard hospital care, can help people hospitalized with severe breathing problems from viruses like COVID-19, flu, or RSV. The goal is to see if it reduces the need for mechanical ventilation or other life support.
Hear when a new Lower Respiratory Tract Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.